IPEC-Americas' Updated Significant Change Guide for Bulk Pharmaceutical Excipients
The recently issued International Pharmaceutical Excipients Council of the Americas Significant Change Guide for Bulk Pharmaceutical Excipients was developed to help excipient manufacturers evaluate the significance of manufacturing changes and to assess the risk that those changes will affect drug...
Gespeichert in:
| Veröffentlicht in: | Pharmaceutical Technology 2005-03, Vol.29 (3), p.98 |
|---|---|
| 1. Verfasser: | |
| Format: | Magazinearticle |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 3 |
| container_start_page | 98 |
| container_title | Pharmaceutical Technology |
| container_volume | 29 |
| creator | Silverstein, Irwin |
| description | The recently issued International Pharmaceutical Excipients Council of the Americas Significant Change Guide for Bulk Pharmaceutical Excipients was developed to help excipient manufacturers evaluate the significance of manufacturing changes and to assess the risk that those changes will affect drug products that contain the excipient. The guideline also explained which changes should prompt communication with drug manufacturers. Recent developments in the business climate have necessitated an update to the significant change guide. Although the significant change guideline focuses on whether a change to an excipient's manufacture warrants notification to a drug manufacturer, the guide serves a secondary purpose as well. A change in an excipient's impurity profile can alert the excipient manufacturer or its customer to the presence of a foreign substance. |
| format | Magazinearticle |
| fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_reports_198233512</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>808276491</sourcerecordid><originalsourceid>FETCH-LOGICAL-p96t-31098b3317c00d7f4035ebc4def97239965b580a73912a2ded8df28cb72ec6b63</originalsourceid><addsrcrecordid>eNotjEFLwzAYQIMoWKf_IZ48BZJ8TZMcZ6lzMHDoPI80-bpVu7Y2KfjzHczTg8fjXZFMCsWZBl1ck0yoHJhUUtySuxi_OJdghMzI-3pblWx5wqn1Lj7RzzG4hIF-tIe-bc6uT7Q8uv6AdDW3AWkzTPR57r7p9uimk_M4p3PV0erXt2OLfYr35KZxXcSHfy7I7qXala9s87Zal8sNG22RGAhuTQ0gtOc86CbnoLD2ecDGagnWFqpWhjsNVkgnAwYTGml8rSX6oi5gQR4v23EafmaMaT_hOEwp7oU1EkAJCX8a-0ra</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>magazinearticle</recordtype><pqid>198233512</pqid></control><display><type>magazinearticle</type><title>IPEC-Americas' Updated Significant Change Guide for Bulk Pharmaceutical Excipients</title><source>Business Source Complete</source><source>Alma/SFX Local Collection</source><creator>Silverstein, Irwin</creator><creatorcontrib>Silverstein, Irwin</creatorcontrib><description>The recently issued International Pharmaceutical Excipients Council of the Americas Significant Change Guide for Bulk Pharmaceutical Excipients was developed to help excipient manufacturers evaluate the significance of manufacturing changes and to assess the risk that those changes will affect drug products that contain the excipient. The guideline also explained which changes should prompt communication with drug manufacturers. Recent developments in the business climate have necessitated an update to the significant change guide. Although the significant change guideline focuses on whether a change to an excipient's manufacture warrants notification to a drug manufacturer, the guide serves a secondary purpose as well. A change in an excipient's impurity profile can alert the excipient manufacturer or its customer to the presence of a foreign substance.</description><identifier>ISSN: 1543-2521</identifier><identifier>EISSN: 2150-7376</identifier><language>eng</language><publisher>Monmouth Junction: MultiMedia Healthcare Inc</publisher><subject>Bovine spongiform encephalopathy ; Consumers ; Flowers & plants ; Genetically modified organisms ; Ingredients ; Manufacturers ; Manufacturing ; Pharmaceutical industry ; Process controls ; Quality control ; Raw materials ; Solvents</subject><ispartof>Pharmaceutical Technology, 2005-03, Vol.29 (3), p.98</ispartof><rights>Copyright Advanstar Communications, Inc. Mar 2005</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>312,776,780,787</link.rule.ids></links><search><creatorcontrib>Silverstein, Irwin</creatorcontrib><title>IPEC-Americas' Updated Significant Change Guide for Bulk Pharmaceutical Excipients</title><title>Pharmaceutical Technology</title><description>The recently issued International Pharmaceutical Excipients Council of the Americas Significant Change Guide for Bulk Pharmaceutical Excipients was developed to help excipient manufacturers evaluate the significance of manufacturing changes and to assess the risk that those changes will affect drug products that contain the excipient. The guideline also explained which changes should prompt communication with drug manufacturers. Recent developments in the business climate have necessitated an update to the significant change guide. Although the significant change guideline focuses on whether a change to an excipient's manufacture warrants notification to a drug manufacturer, the guide serves a secondary purpose as well. A change in an excipient's impurity profile can alert the excipient manufacturer or its customer to the presence of a foreign substance.</description><subject>Bovine spongiform encephalopathy</subject><subject>Consumers</subject><subject>Flowers & plants</subject><subject>Genetically modified organisms</subject><subject>Ingredients</subject><subject>Manufacturers</subject><subject>Manufacturing</subject><subject>Pharmaceutical industry</subject><subject>Process controls</subject><subject>Quality control</subject><subject>Raw materials</subject><subject>Solvents</subject><issn>1543-2521</issn><issn>2150-7376</issn><fulltext>true</fulltext><rsrctype>magazinearticle</rsrctype><creationdate>2005</creationdate><recordtype>magazinearticle</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNotjEFLwzAYQIMoWKf_IZ48BZJ8TZMcZ6lzMHDoPI80-bpVu7Y2KfjzHczTg8fjXZFMCsWZBl1ck0yoHJhUUtySuxi_OJdghMzI-3pblWx5wqn1Lj7RzzG4hIF-tIe-bc6uT7Q8uv6AdDW3AWkzTPR57r7p9uimk_M4p3PV0erXt2OLfYr35KZxXcSHfy7I7qXala9s87Zal8sNG22RGAhuTQ0gtOc86CbnoLD2ecDGagnWFqpWhjsNVkgnAwYTGml8rSX6oi5gQR4v23EafmaMaT_hOEwp7oU1EkAJCX8a-0ra</recordid><startdate>20050301</startdate><enddate>20050301</enddate><creator>Silverstein, Irwin</creator><general>MultiMedia Healthcare Inc</general><scope>0U~</scope><scope>1-H</scope><scope>3V.</scope><scope>7RN</scope><scope>7RQ</scope><scope>7RV</scope><scope>7WY</scope><scope>7WZ</scope><scope>7XB</scope><scope>87Z</scope><scope>883</scope><scope>889</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FL</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BEZIV</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FRNLG</scope><scope>FYUFA</scope><scope>F~G</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K60</scope><scope>K6~</scope><scope>KB0</scope><scope>L.-</scope><scope>L.0</scope><scope>M0C</scope><scope>M0F</scope><scope>M2O</scope><scope>M2P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQBIZ</scope><scope>PQBZA</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>S0X</scope><scope>U9A</scope></search><sort><creationdate>20050301</creationdate><title>IPEC-Americas' Updated Significant Change Guide for Bulk Pharmaceutical Excipients</title><author>Silverstein, Irwin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p96t-31098b3317c00d7f4035ebc4def97239965b580a73912a2ded8df28cb72ec6b63</frbrgroupid><rsrctype>magazinearticle</rsrctype><prefilter>magazinearticle</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Bovine spongiform encephalopathy</topic><topic>Consumers</topic><topic>Flowers & plants</topic><topic>Genetically modified organisms</topic><topic>Ingredients</topic><topic>Manufacturers</topic><topic>Manufacturing</topic><topic>Pharmaceutical industry</topic><topic>Process controls</topic><topic>Quality control</topic><topic>Raw materials</topic><topic>Solvents</topic><toplevel>online_resources</toplevel><creatorcontrib>Silverstein, Irwin</creatorcontrib><collection>Global News & ABI/Inform Professional</collection><collection>Trade PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Pharmaceutical News Index</collection><collection>Career & Technical Education Database</collection><collection>Nursing & Allied Health Database</collection><collection>ABI/INFORM Collection</collection><collection>ABI/INFORM Global (PDF only)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ABI/INFORM Global (Alumni Edition)</collection><collection>ABI/INFORM Trade & Industry (Alumni Edition)</collection><collection>Pharmaceutical News Index (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection (Alumni Edition)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Business Premium Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Business Premium Collection (Alumni)</collection><collection>Health Research Premium Collection</collection><collection>ABI/INFORM Global (Corporate)</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Business Collection (Alumni Edition)</collection><collection>ProQuest Business Collection</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ABI/INFORM Professional Advanced</collection><collection>ABI/INFORM Professional Standard</collection><collection>ABI/INFORM Global</collection><collection>ABI/INFORM Trade & Industry</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Business</collection><collection>ProQuest One Business (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><jtitle>Pharmaceutical Technology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Silverstein, Irwin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>IPEC-Americas' Updated Significant Change Guide for Bulk Pharmaceutical Excipients</atitle><jtitle>Pharmaceutical Technology</jtitle><date>2005-03-01</date><risdate>2005</risdate><volume>29</volume><issue>3</issue><spage>98</spage><pages>98-</pages><issn>1543-2521</issn><eissn>2150-7376</eissn><abstract>The recently issued International Pharmaceutical Excipients Council of the Americas Significant Change Guide for Bulk Pharmaceutical Excipients was developed to help excipient manufacturers evaluate the significance of manufacturing changes and to assess the risk that those changes will affect drug products that contain the excipient. The guideline also explained which changes should prompt communication with drug manufacturers. Recent developments in the business climate have necessitated an update to the significant change guide. Although the significant change guideline focuses on whether a change to an excipient's manufacture warrants notification to a drug manufacturer, the guide serves a secondary purpose as well. A change in an excipient's impurity profile can alert the excipient manufacturer or its customer to the presence of a foreign substance.</abstract><cop>Monmouth Junction</cop><pub>MultiMedia Healthcare Inc</pub></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1543-2521 |
| ispartof | Pharmaceutical Technology, 2005-03, Vol.29 (3), p.98 |
| issn | 1543-2521 2150-7376 |
| language | eng |
| recordid | cdi_proquest_reports_198233512 |
| source | Business Source Complete; Alma/SFX Local Collection |
| subjects | Bovine spongiform encephalopathy Consumers Flowers & plants Genetically modified organisms Ingredients Manufacturers Manufacturing Pharmaceutical industry Process controls Quality control Raw materials Solvents |
| title | IPEC-Americas' Updated Significant Change Guide for Bulk Pharmaceutical Excipients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T00%3A45%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=IPEC-Americas'%20Updated%20Significant%20Change%20Guide%20for%20Bulk%20Pharmaceutical%20Excipients&rft.jtitle=Pharmaceutical%20Technology&rft.au=Silverstein,%20Irwin&rft.date=2005-03-01&rft.volume=29&rft.issue=3&rft.spage=98&rft.pages=98-&rft.issn=1543-2521&rft.eissn=2150-7376&rft_id=info:doi/&rft_dat=%3Cproquest%3E808276491%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=198233512&rft_id=info:pmid/&rfr_iscdi=true |